novel
human
coronaviru
caus
sever
acut
respiratori
syndrom
sar
emerg
epidem
form
earli
china
spread
worldwid
month
everi
newli
emerg
human
pathogen
concern
safeti
blood
suppli
epidem
crisi
purpos
evalu
inactiv
sarscoronaviru
cov
platelet
concentr
use
approv
pathogen
inactiv
devic
intercept
blood
system
apheresi
platelet
concentr
apc
inocul
approxim
pfu
ml
either
urbani
isol
sarscov
inocul
unit
mix
mm
amotosalen
illumin
j
cm
uva
light
viral
titr
determin
plaqu
format
vero
cell
mix
sarscov
apc
absenc
treatment
decreas
viral
infect
approxim
log
follow
photochem
treatment
sarscov
consist
inactiv
limit
detect
seven
independ
apc
unit
infecti
viru
detect
treatment
onethird
apc
unit
assay
demonstr
mean
log
reduct
potent
inactiv
sarscov
therefor
extend
capabl
intercept
blood
system
inactiv
broad
spectrum
human
pathogen
includ
recent
emerg
respiratori
virus
key
word
amotosalen
photochem
inactiv
platelet
concentr
sarscoronaviru
platelet
transfus
may
result
transmiss
viral
bacteri
diseas
caus
advers
immun
reaction
advent
specif
sensit
test
viral
contamin
greatli
reduc
transfusionassoci
transmiss
select
viral
diseas
goodnough
et
al
nevertheless
multilay
test
elimin
viral
contamin
test
insensit
detect
presenc
pathogen
window
period
seroconvers
infect
donor
dodd
et
al
regard
collect
blood
window
period
like
import
sourc
transfusionassoci
human
immunodefici
viru
hiv
infect
busch
et
al
nucleic
acid
test
minipool
mpnat
reduc
although
elimin
window
period
newli
infect
donor
may
detect
low
hiv
load
acut
phase
phelp
et
al
potenti
donor
silent
chronic
viral
infect
hepat
b
viru
hbv
may
low
viral
burden
without
detect
antivir
antibodi
thu
remain
undetect
mpnat
allain
combin
serolog
test
mpnat
place
residu
risk
contamin
select
virus
decreas
less
human
tcell
leukaemia
viru
htlviii
less
hepat
c
viru
less
hbv
goodnough
et
al
dodd
et
al
although
improv
safeti
blood
compon
test
remain
reactiv
approach
blood
safeti
contamin
organ
must
identifi
sensit
test
develop
new
pathogen
west
nile
viru
continu
enter
donor
popul
may
transmit
sensit
test
place
harrington
et
al
recent
emerg
new
strain
pathogen
virus
sever
acut
respiratori
syndrom
coronaviru
sarscov
demonstr
suscept
world
blood
suppli
previous
unknown
virus
spread
global
short
amount
time
mahoni
et
al
yu
et
al
sar
emerg
china
spread
sever
countri
worldwid
month
result
infect
peopl
caus
death
novemb
septemb
world
health
organ
novel
human
coronaviru
sarscov
consist
isol
sar
patient
three
differ
contin
independ
ksiazek
et
al
peiri
et
al
vicenzi
et
al
human
human
sarscov
transmiss
contain
year
lipsitch
et
al
howev
animalhuman
transmiss
also
document
impli
viru
could
reemerg
fact
diseas
probabl
trigger
anim
viru
acquir
abil
infect
human
case
may
imposs
fulli
erad
viru
particularli
natur
host
wild
rather
domest
anim
holm
human
sarscov
transmiss
occur
close
contact
symptomat
infect
individu
wu
et
al
thu
far
evid
viru
transmit
blood
suppli
although
viraem
phase
describ
first
week
onset
ill
grant
et
al
schmidt
et
al
howev
possibl
introduct
sarscov
blood
suppli
prevent
avoid
reemerg
infecti
agent
human
human
rout
regard
pathogen
inactiv
technolog
offer
proactiv
approach
potenti
improv
blood
safeti
reduc
risk
associ
platelet
transfus
intercept
blood
system
photochem
treatment
pct
process
util
combin
amotosalen
hcl
longwavelength
ultraviolet
light
develop
introduc
clinic
practic
europ
wollowitz
vitro
studi
extens
clinic
test
demonstr
pct
inactiv
broad
spectrum
pathogen
preserv
haemostat
properti
platelet
van
rhenen
et
al
mccullough
et
al
studi
demonstr
intercept
blood
system
inactiv
high
level
sarscov
inocul
platelet
concentr
addit
array
human
pathogen
alreadi
proven
kill
system
grass
et
al
lin
et
al
therefor
observ
extend
capabl
intercept
blood
system
inactiv
broad
spectrum
human
pathogen
includ
recent
emerg
viral
pathogen
sarscov
experi
conduct
apheresi
platelet
concentr
apc
collect
amicu
cell
separ
baxter
healthcar
deerfield
il
usa
apc
contain
platelet
suspend
approxim
ml
plasma
intersol
also
known
pa
iii
pl
plastic
contain
baxter
healthcar
pct
perform
use
amotosalen
hcl
mm
uva
light
nm
process
devic
util
close
system
consist
seri
plastic
contain
illumin
sourc
fig
experi
use
microprocessorcontrol
ultraviolet
illumin
system
capabl
process
two
platelet
unit
time
model
baxter
healthcar
ultraviolet
illumin
system
deliv
j
cm
uva
treatment
dose
platelet
unit
min
illumin
devic
use
fluoresc
lamp
mount
illumin
tray
aircool
temperatur
control
apc
illumin
devic
agit
reciproc
shake
viral
isol
obtain
inocul
vero
cell
atcc
rockvil
md
usa
sputum
specimen
italian
patient
affect
sever
form
pneumonia
unknown
aetiolog
histori
travel
vietnam
itali
march
amplif
second
passag
viru
entir
genom
sequenc
report
genbank
access
number
vicenzi
et
al
viral
stock
obtain
vero
cell
two
addit
serial
passag
urbani
strain
sarscov
specimen
number
strain
receiv
center
diseas
control
cdc
atlanta
ga
usa
viral
stock
prepar
cultur
supernat
infect
vero
cell
atcc
centrifug
remov
cell
debri
five
replic
experi
perform
sarscov
strain
fullsiz
apc
unit
unit
ml
plasma
intersol
spike
approxim
plaqueform
unit
per
ml
pfu
ml
sarscov
aliquot
apc
test
min
determin
pretreat
viral
infect
titr
spike
platelet
mixtur
treat
mm
amotosalen
j
cm
uva
light
briefli
use
steril
connect
devic
scd
apc
contain
spike
sarscov
sterileconnect
seri
amotosalen
contain
fig
step
apc
plasmaintersol
pass
amotosalen
contain
illumin
contain
air
express
illumin
contain
contain
platelet
concentr
amotosalen
sarscov
subsequ
separ
amotosalen
contain
heat
seal
step
amotosalenplatelet
mixtur
place
illumin
devic
platelet
mixtur
expos
j
cm
treatment
uva
agit
cycl
min
treatment
sampl
collect
measur
posttreat
viral
infect
titr
replic
experi
use
independ
unit
apc
infecti
viral
titr
measur
use
standard
plaqu
assay
vero
cell
plaqu
assay
platelet
sampl
first
dilut
tissu
cultur
medium
mix
cacl
final
concentr
mm
incub
approxim
least
h
allow
time
clot
format
remov
centrifug
clotfre
supernat
use
viral
plaqu
assay
two
five
replic
ml
approxim
onethird
apc
unit
assay
residu
infecti
viru
larger
volum
assay
increas
dynam
rang
plaqu
assay
urbani
strain
sarscov
evalu
sensit
inactiv
apc
two
independ
experi
test
unit
contain
ml
apc
suspend
plasma
intersol
instead
fullsiz
ml
apc
unit
aliquot
spike
approxim
pfu
ml
viru
treat
mm
amotosalen
j
cm
uva
light
treatment
ml
apc
assay
residu
infect
titr
plaqu
assay
vero
cell
sampl
heparin
sulphat
u
ml
ad
diluent
plaqu
assay
prevent
clot
sampl
test
unit
contain
sarscov
serial
dilut
cell
cultur
media
either
eagl
minim
essenti
medium
earl
salt
dulbecco
modifi
eagl
medium
dmem
biowhittak
vervier
belgium
supplement
fetal
calf
serum
hyclon
perbio
scienc
erembodegem
aalst
belgium
inocul
onto
vero
cell
monolay
approxim
h
test
sampl
aspir
step
iiiumin
step
cad
step
step
dispos
set
provid
singleus
close
integr
system
pathogen
inactiv
treatment
platelet
product
ml
platelet
product
mixtur
plasma
intersol
also
known
pa
iii
connect
via
steril
connect
devic
scd
pass
contain
amotosalen
hcl
also
known
illumin
contain
step
integr
set
place
uva
illumin
devic
provid
three
j
cm
dose
uva
light
mixtur
step
illumin
min
platelet
transfer
second
contain
treatment
compound
adsorpt
devic
cad
lower
level
residu
amotosalen
free
photoproduct
step
minimum
h
cad
treatment
photochem
treatment
platelet
transfer
pl
plastic
contain
storag
day
step
cad
step
use
viral
inactiv
experi
describ
report
adher
cell
layer
overlay
media
contain
either
agaros
seaplaqu
fmc
bioproduct
rockland
usa
carboxymethylcellulos
sigma
chemic
corp
st
loui
ms
usa
day
incub
plaqu
number
score
visual
stain
necessari
neutral
red
sigma
crystal
violet
sigma
methanol
viral
rna
spike
apc
extract
use
quiagen
viral
rna
mini
kit
quiagen
inc
santa
clarita
ca
usa
accord
manufactur
instruct
quantif
viral
rna
perform
use
realtim
polymeras
chain
reaction
pcr
taqman
assay
gener
cdna
vicenzi
et
al
follow
primer
pair
probe
ttatcacccgcg
aagaagct
ctctagttgca
tgacagccctc
bnitmsarp
tgc
gtg
gat
tgg
ctt
tga
ad
univers
pcr
master
mix
appli
biosystem
foster
citi
ca
usa
nm
respect
final
volum
ml
standard
obtain
clone
fragment
plasmid
use
ta
clone
kit
vitrogen
corp
san
diego
ca
usa
linear
distribut
r
obtain
copi
data
shown
level
viral
inactiv
calcul
log
use
formula
log
reduct
log
pretreat
viral
titreposttreat
viral
titr
pct
viru
detect
viral
titr
express
v
infecti
unit
v
total
platelet
volum
assay
lack
viru
detect
indic
inactiv
limit
detect
thu
log
reduct
express
greater
input
titr
volum
platelet
concentr
assay
preliminari
experi
carri
order
measur
sarscov
infect
mix
apc
absenc
amotosalen
uva
light
treatment
purpos
sarscov
urbani
viral
infect
cultur
medium
compar
viral
infect
spike
platelet
concentr
incub
platelet
mixtur
durat
experi
result
show
mean
decreas
viral
infect
titr
approxim
log
mix
platelet
similarli
sarscov
inocul
platelet
unit
order
exceed
total
apc
volum
ml
viral
stock
ad
ml
platelet
concentr
mix
viru
apc
aliquot
remov
clot
format
retract
carri
describ
materi
method
supernat
either
test
plaqu
infect
assay
subject
rna
extract
quantif
viral
genom
incub
sarscov
control
apc
ad
amotosalen
uva
light
period
experi
result
approxim
log
reduct
viral
titr
ae
ae
log
pfu
ml
viral
input
ae
copi
ml
measur
realtim
revers
transcriptionpolymeras
chain
reaction
approxim
log
higher
titr
obtain
plaqu
assay
confirm
previou
observ
indic
approxim
viral
genom
requir
form
singl
plaqu
vicenzi
et
al
intercept
blood
system
inactiv
high
titr
urbani
isol
sarscov
tabl
five
replic
experi
strain
sarscov
pretreat
infect
titr
rang
pfuml
apc
treatment
viabl
viru
detect
test
volum
ml
demonstr
mean
log
reduct
ae
rang
assay
ml
treat
platelet
sampl
increas
dynam
rang
plaqu
assay
demonstr
log
reduct
similarli
two
replic
experi
sarscov
urbani
strain
pretreat
infect
titr
pfu
ml
apc
treatment
viabl
viru
detect
test
volum
three
ml
demonstr
inactiv
log
viral
infect
respect
taken
togeth
seven
replic
mean
log
reduct
obtain
result
show
sarscov
highli
sensit
pct
amotosalen
uva
present
studi
demonstr
sarscov
inactiv
platelet
concentr
limit
detect
mean
log
ae
rang
achiev
treatment
intercept
blood
system
efficaci
pathogen
inactiv
intercept
blood
system
demonstr
two
differ
sarscov
viral
isol
effect
pathogen
inactiv
system
blood
compon
must
broadspectrum
inactiv
capabl
maintain
biolog
properti
blood
compon
develop
intercept
blood
system
platelet
describ
report
studi
perform
demonstr
inactiv
bacteria
virus
protozoa
leucocyt
platelet
concentr
vanvoorhi
et
al
report
demonstr
amotosalen
plu
uva
inactiv
sarscov
novel
human
coronaviru
caus
sar
effect
inactiv
demonstr
two
independ
viral
isol
phylogenet
analysi
show
two
strain
employ
studi
common
origin
similar
origin
hong
kong
north
china
taiwan
vega
et
al
vicenzi
et
al
nucleotid
sequenc
comparison
urbani
isol
differ
six
nucleotid
chang
isol
ruan
et
al
vicenzi
et
al
regard
differ
two
isol
consist
low
mutat
rate
sarscov
sarscov
shown
lowest
mutat
frequenc
among
rna
virus
yeh
et
al
potenti
sarscov
transmiss
blood
suppli
unknown
wherea
close
contact
symptomat
patient
main
rout
transmiss
tong
liang
sarscov
howev
detect
blood
infect
individu
grant
et
al
yam
et
al
current
nat
assay
howev
import
limit
detect
sarscov
infect
individu
first
week
symptom
drosten
et
al
ng
et
al
falseneg
nat
result
occur
due
pcr
inhibitor
faulti
rna
extract
falseposit
nat
result
also
report
consequ
trigger
alarm
bell
worldwid
yu
realtim
pcr
assay
modifi
order
improv
specif
sensit
lau
et
al
poon
et
al
window
period
detect
sarscov
blood
remain
undefin
regard
postul
time
cours
sarscov
viremia
may
rel
short
viral
load
low
detect
day
onset
symptom
ng
et
al
addit
preval
individu
infect
sarscov
highrisk
area
remain
unknown
recent
report
support
exist
sub
clinic
nonpneumon
sarscov
infect
woo
et
al
nonpneumon
sarscov
infect
present
healthi
blood
donor
sar
outbreak
hong
kong
woo
et
al
although
level
sarscov
viremia
report
signific
correspond
howev
gener
respond
cast
doubt
woo
find
yip
et
al
theron
young
zhou
nevertheless
pathogen
inactiv
proactiv
approach
blood
safeti
preemptiv
deal
new
emerg
agent
affect
safeti
blood
suppli
without
necessarili
know
level
infecti
particl
blood
stream
intercept
blood
system
util
amotosalen
uva
light
shown
inactiv
bacteria
virus
protozoa
leucocyt
lin
et
al
vanvoorhi
et
al
lin
et
al
sign
indic
infecti
viru
detect
volum
assay
sign
indic
inactiv
limit
detect
intercept
blood
system
nucleic
acidtarget
technolog
requir
specif
viral
sequenc
aggreg
data
demonstr
pct
broadspectrum
efficaci
varieti
envelop
nonenvelop
rna
dna
known
emerg
virus
platelet
concentr
therefor
offer
potenti
prospect
prevent
major
platelet
transfusionassoci
viral
diseas
